LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer Meeting Abstract
| Authors: | de Azambuja, E.; Saura, C.; Oliveira, M.; Dubsky, P. C.; Zardavas, D.; Fesl, C.; Bardia, A.; Lin, R.; Fredrickson, J. O.; Parmar, H.; Singel, S. M.; Hsu, J. Y.; Piccart-Gebhart, M. J.; Gnant, M.; Baselga, J. |
| Abstract Title: | LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036904819 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.TPS627 |
| Notes: | Meeting Abstract: TPS627 -- Source: Wos |
